MannKind to Present at Upcoming Conferences
August 27 2024 - 4:30PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of innovative
inhaled therapeutic products and devices for patients with
endocrine and orphan lung diseases, announced today that Chief
Executive Officer Michael Castagna, PharmD, and Chief Financial
Officer Chris Prentiss will share updates during fireside chats at
three upcoming investor conferences:
2024 Wells Fargo Healthcare
Conference in BostonWednesday, September 411:00 a.m.
Eastern Time
Morgan Stanley 22nd
Annual Global Healthcare Conference in New
YorkFriday, September 67:00 a.m. Eastern Time
H.C. Wainwright 26th
Annual Global Investment Conference in New
YorkTuesday, September 109:30 a.m. Eastern Time
Links to access live audio webcasts of the sessions will be
available on MannKind Corporation’s website at:
https://investors.mannkindcorp.com/events-and-presentations. An
archived, recorded version will also be available on the website
for approximately 30 days following each conference.
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative inhaled therapeutic products and devices to address
serious unmet medical needs for those living with endocrine and
orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, nontuberculous mycobacterial (NTM) lung disease,
pulmonary fibrosis, and pulmonary hypertension. Our signature
technologies – dry-powder formulations and inhalation devices –
offer rapid and convenient delivery of medicines to the deep lung
where they can exert an effect locally or enter the systemic
circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, X or Instagram.
MANNKIND is a registered trademark of MannKind Corporation.
For MannKind:
Christie Iacangelo
Corporate Communications
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2024 to Aug 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2023 to Aug 2024